dc.contributor.author | Serin, Ayfer | |
dc.contributor.author | Tokat, Yaman | |
dc.date.accessioned | 2020-12-02T18:01:48Z | |
dc.date.available | 2020-12-02T18:01:48Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 0041-1345 | |
dc.identifier.issn | 1873-2623 | |
dc.identifier.uri | https://doi.org/10.1016/j.transproceed.2019.01.163 | |
dc.identifier.uri | http://hdl.handle.net/11446/3729 | |
dc.description | 1st International Transplant Network Congress -- OCT 17-21, 2018 -- Antalya, TURKEY | en_US |
dc.description | WOS: 000487349900073 | en_US |
dc.description | PubMed: 31405744 | en_US |
dc.description.abstract | Purpose. Data on recurrence of hepatitis D virus (HDV) and its long-term impact on liver transplant (LT) are limited. in this study, we investigated the incidence of hepatitis B virus (HBV) and the long-term effect of postoperative HDV recurrence HDV coinfection in our liver transplant patients. Patients and Methods. Between 2004 and 2018, all patients with LT because of HBV (n = 361; 37.3%) were reviewed, and those with HBV and HDV coinfection (n = 104; 30% of all HBV patients) were enrolled in our study. All patients received post-transplant combination therapy with nucleos(t)ide analogue and antihepatitis B immunoglobulins. Breakthrough infection was defined as reemergence of HBV DNA or hepatitis B surface antigen during postoperative treatment. in case of recurrence, another oral nucleos(t)ide analogue was added and antihepatitis B immunoglobulins were stopped. Results. During the study period, the frequency of HDV (+) was decreased (41% to 14%). Median follow-up time was 82 months (range, 1-274 months). Post LT survival and HBV recurrence were 97% (n = 15) and 13.4%, respectively. Only 15 patients (14%) developed breakthrough infection. There was no predictive factor for recurrent HDV infection, including demographics data and concomitant hepatocellular carcinoma (P = .73). Mortality was similar between patients with and without recurrence (2.2% vs 7.1%, P = .35) Conclusions. Patients who received transplants for hepatitis B and D virus cirrhosis had favorable prognosis and good long-term results despite recurrent infection. Close follow-up of patients and effective postoperative viral suppression with appropriate medications seems to be favorable for both prevention and management of recurrence and provides comparable outcome with patients without recurrence. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier Science Inc | en_US |
dc.identifier.doi | 10.1016/j.transproceed.2019.01.163 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.title | Recurrence of Hepatitis D Virus in Liver Transplant Recipients With Hepatitis B and D Virus-Related Chronic Liver Disease | en_US |
dc.type | conferenceObject | en_US |
dc.relation.journal | Transplantation Proceedings | en_US |
dc.department | DBÜ | en_US |
dc.identifier.issue | 7 | en_US |
dc.identifier.volume | 51 | en_US |
dc.identifier.startpage | 2457 | en_US |
dc.identifier.endpage | 2460 | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.department-temp | [Serin, Ayfer] 230 Pk Ave, New York, NY 10169 USA | en_US |